Treatment selection for Stage IV BC is guided by tumor expression of targetable receptors, including the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) (3, 4). This evidence concerns the gene ERBB2 and neoplasm.